BioPharmSignal logoBioPharmSignal

Biotech News

Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts

Oculis (OCS)OculisEarnings

Licaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated around year-end 2026. Privosegtor (PIONEER-1): Advancing global registrational trial in optic

Related news

OCSOculis2026-08-06 20:05 EST

Oculis Reports Q2 2026 Financial Results and Provides Company Update

MGTXMeiraGTx2026-08-13 12:00 EST

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

BLTEBelite Bio2026-08-13 01:45 EST

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

EYPTEyePoint Pharmaceuticals2026-08-05 11:00 EST

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

LCTXLineage Cell Therapeutics2026-11-05 13:00 EST

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

LENZLenz Therapeutics Inc2026-10-28 20:30 EST

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

OCGNOcugen2026-10-22 11:00 EST

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

LENZLenz Therapeutics Inc2026-08-11 20:05 EST

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

KPRXKiora Pharmaceuticals2026-08-07 11:00 EST

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-11-03 21:05 EST

Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts

OCSOculis2026-11-02 07:00 EST

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

OCSOculis2026-10-29 09:39 EST

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

OCSOculis2026-10-22 06:00 EST

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

OCSOculis2026-10-20 06:00 EST

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Stock data

Close
6.83 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States